IN2014DN07888A - - Google Patents

Info

Publication number
IN2014DN07888A
IN2014DN07888A IN7888DEN2014A IN2014DN07888A IN 2014DN07888 A IN2014DN07888 A IN 2014DN07888A IN 7888DEN2014 A IN7888DEN2014 A IN 7888DEN2014A IN 2014DN07888 A IN2014DN07888 A IN 2014DN07888A
Authority
IN
India
Prior art keywords
nanostructures
cells
compositions
cases
conditions
Prior art date
Application number
Inventor
C Shad Thaxton
Marina G Damiano
Heng Zhang
Kaylin M Mcmahon
Shuo Yang
Leo I Gordon
Amareshwar T K Singh
Original Assignee
Univ Northwestern
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Northwestern filed Critical Univ Northwestern
Publication of IN2014DN07888A publication Critical patent/IN2014DN07888A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Nanostructures compositions and methods for treating cancers and other conditions are provided. In some cases the nanostructures and/or compositions may be used to treat cancers or other diseases or conditions at least in part by controlling cholesterol metabolism in cells. The nanostructures and compositions may be used for example to control cholesterol influx and/or efflux in cells. In some cases the nanostructures or compositions may be used to kill the cells. Examples of cancer cells that may be affected by the nanostructures and compositions described herein include those having scavenger receptor type B-I (SR-B1) B-cell lymphoma cells non-Hodgkin's lymphoma cells melanoma cells and/or others. In some embodiments the nanostructures may be mimics of natural high density lipoprotein (HDL).
IN7888DEN2014 2012-02-22 2013-02-22 IN2014DN07888A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261601706P 2012-02-22 2012-02-22
PCT/US2013/027431 WO2013126776A1 (en) 2012-02-22 2013-02-22 Nanostructures for treating cancers and other conditions

Publications (1)

Publication Number Publication Date
IN2014DN07888A true IN2014DN07888A (en) 2015-04-24

Family

ID=47833440

Family Applications (1)

Application Number Title Priority Date Filing Date
IN7888DEN2014 IN2014DN07888A (en) 2012-02-22 2013-02-22

Country Status (11)

Country Link
US (1) US20150064255A1 (en)
EP (2) EP2817024B1 (en)
JP (1) JP2015513543A (en)
KR (1) KR20140123597A (en)
CN (1) CN104244965A (en)
AU (1) AU2013222238A1 (en)
CA (1) CA2865279C (en)
ES (1) ES2745208T3 (en)
IN (1) IN2014DN07888A (en)
MX (1) MX2014010161A (en)
WO (1) WO2013126776A1 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5204646B2 (en) 2005-04-25 2013-06-05 マサチューセッツ インスティテュート オブ テクノロジー Compositions and methods for promoting hemostasis and other physiological activities
US9084837B2 (en) 2006-04-25 2015-07-21 Massachusetts Institute Of Technology Compositions and methods for affecting movement of contaminants, bodily fluids or other entities, and/or affecting other physiological conditions
JP5539962B2 (en) 2008-04-25 2014-07-02 ノースウェスタン、ユニバーシティ Nanostructure suitable for sequestering cholesterol
US9439941B2 (en) 2009-12-14 2016-09-13 The University Of Hong Kong Nano cancer barrier device (NCBD) to immobilize and inhibit the division of metastic cancer stem cells
US20130034599A1 (en) 2010-01-19 2013-02-07 Northwestern University Synthetic nanostructures including nucleic acids and/or other entities
EP2691101A2 (en) 2011-03-31 2014-02-05 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
KR20140102759A (en) 2011-12-16 2014-08-22 모더나 세라퓨틱스, 인코포레이티드 Modified nucleoside, nucleotide, and nucleic acid compositions
JP6144355B2 (en) 2012-11-26 2017-06-07 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． Chemically modified mRNA
CA2897941A1 (en) 2013-01-17 2014-07-24 Moderna Therapeutics, Inc. Signal-sensor polynucleotides for the alteration of cellular phenotypes
US10258698B2 (en) 2013-03-14 2019-04-16 Modernatx, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
US10894963B2 (en) 2013-07-25 2021-01-19 Exicure, Inc. Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use
US10568898B2 (en) 2013-08-13 2020-02-25 Northwestern University Lipophilic nanoparticles for drug delivery
US10413565B2 (en) 2014-04-30 2019-09-17 Northwestern University Nanostructures for modulating intercellular communication and uses thereof
US10220046B2 (en) 2014-07-14 2019-03-05 The Regents Of The University Of Michigan Compositions and methods for disease treatment using nanoparticle delivered compounds
CA2963931A1 (en) 2014-10-06 2016-04-14 Exicure, Inc. Anti-tnf compounds
WO2016085986A1 (en) * 2014-11-24 2016-06-02 Northwestern University High density lipoprptein nanoparticles for inflammation
US10307491B2 (en) 2015-01-30 2019-06-04 The Regents Of The University Of Michigan Liposomal particles comprising biological molecules and uses thereof
US10078092B2 (en) 2015-03-18 2018-09-18 Northwestern University Assays for measuring binding kinetics and binding capacity of acceptors for lipophilic or amphiphilic molecules
WO2016154544A1 (en) 2015-03-25 2016-09-29 The Regents Of The University Of Michigan Compositions and methods for delivery of biomacromolecule agents
US10967072B2 (en) 2016-04-27 2021-04-06 Northwestern University Short interfering RNA templated lipoprotein particles (siRNA-TLP)
CN113939278A (en) * 2019-04-26 2022-01-14 西北大学 High density lipoprotein nanoparticles and RNA-templated lipoprotein particles for ocular therapy
EP3965746A4 (en) * 2019-05-10 2023-07-19 Northwestern University Orally delivered lipid nanoparticles target and reveal gut cd36 as a master regulator of systemic lipid homeostasis with differential gender responses
CN115003312A (en) * 2019-09-18 2022-09-02 西北大学 High density lipoprotein-like nanoparticles as inducers of iron death in cancer
CN112569207A (en) * 2019-09-30 2021-03-30 复旦大学 Apolipoprotein-modified bionic nano tumor vaccine and preparation method and application thereof
KR102614058B1 (en) * 2022-06-13 2023-12-15 (주) 멥스젠 Reconstituted high-density lipoprotein nanoparticles for drug delivery

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007089607A2 (en) * 2006-01-26 2007-08-09 University Of Massachusetts Rna silencing agents for use in therapy and nanotransporters for efficient delivery of same
CA2708719A1 (en) * 2007-12-12 2009-06-18 University Health Network High-density lipoprotein-like peptide-phospholipid scaffold ("hpps") nanoparticles
JP5539962B2 (en) 2008-04-25 2014-07-02 ノースウェスタン、ユニバーシティ Nanostructure suitable for sequestering cholesterol
US20130034599A1 (en) * 2010-01-19 2013-02-07 Northwestern University Synthetic nanostructures including nucleic acids and/or other entities

Also Published As

Publication number Publication date
AU2013222238A1 (en) 2014-09-18
JP2015513543A (en) 2015-05-14
KR20140123597A (en) 2014-10-22
CA2865279A1 (en) 2013-08-29
EP3597209A1 (en) 2020-01-22
CA2865279C (en) 2023-04-25
CN104244965A (en) 2014-12-24
US20150064255A1 (en) 2015-03-05
ES2745208T3 (en) 2020-02-28
MX2014010161A (en) 2015-03-09
EP2817024B1 (en) 2019-07-10
EP2817024A1 (en) 2014-12-31
WO2013126776A1 (en) 2013-08-29

Similar Documents

Publication Publication Date Title
IN2014DN07888A (en)
MY166014A (en) Combination therapy methods for treating proliferative diseases
PH12014501351A1 (en) Fluorinated estrogen receptor modulators and uses thereof
UA99839C2 (en) Benzodiazepinone compounds useful in the treatment of skin conditions
MX2014010455A (en) Methods and compositions for treating huntington's disease.
NZ709215A (en) Compositions comprising anti-cd38 antibodies and lenalidomide
MY162903A (en) Methods of treatment of pancreatic cancer
PH12015501737A1 (en) Androgen receptor modulators and uses thereof
NZ715201A (en) Afucosylated anti-fgfr2iiib antibodies
EP3587558A3 (en) Methods of populating a gastrointestinal tract
PH12015500879A1 (en) Compositions and methods for treating proteinopathies
IN2015KN00414A (en)
PE20150223A1 (en) ANTIBODIES ENHANCED ANTIBODIES AGAINST GROWTH AND DIFFERENTIATION FACTOR-8 AND THE USES OF THEM
SG10201808661XA (en) Method of treating obesity using antioxidant inflammation modulators
MX362185B (en) Compositions and treatment for eye diseases and disorders.
GB201318761D0 (en) Compounds for the treatment of neuropsychiatric disorders
WO2010132697A3 (en) Methods and compositions for treatment
WO2012170947A3 (en) Methods for modulating factor 12 expression
DK2714888T3 (en) RECOMBINANT DO
IN2014CN03610A (en)
MX2014002967A (en) Antagonists of products of the hs.459642 unigene cluster for the inhibition of proliferation, development or differentiation of stem cells including cancer stem cells.
MX2014010713A (en) Procaspase 3 activation by combination therapy.
MX2013013649A (en) Quinone compounds for treating ape1 mediated diseases.
MX366380B (en) Prebiotic oral care compositions containing an alkyl glycoside.
MX2021010349A (en) Composition for preventing, alleviating, or treating obesity or fatty liver disease, comprising weissella hellenica wikim0103.